FRM
COLL icon

Fox Run Management’s Collegium Pharmaceutical COLL Stock Holding History

Fox Run Management’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,462
Closed -$253K – 947
2025
Q4 		$253K Buy
+5,462
New +$229K 0.04% 740
2024
Q2 		– Sell
-5,401
Closed -$210K – 822
2024
Q1 		$210K Buy
+5,401
New +$189K 0.05% 622
2018
Q2 		– Sell
-8,634
Closed -$221K – 704
2018
Q1 		$221K Buy
+8,634
New +$206K 0.05% 598

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Fox Run Management's COLL Position: Q1 2026 in Review

Fox Run Management sold out of Collegium Pharmaceutical (COLL) in Q1 2026, closing a stake of 5,462 shares — an estimated $253K sold.

Fox Run Management first reported a position in COLL in Q1 2018 and held it in 3 quarters. The position peaked at $253K in Q4 2025. 267 funds tracked by Wall St. Rank hold COLL as of Q1 2026.

  • Fox Run Management reported no remaining Collegium Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 5,462 Collegium Pharmaceutical shares in Q1 2026, an estimated $253K.
  • Fox Run Management first reported a position in Collegium Pharmaceutical in Q1 2018 and held it in 3 quarters.
  • Fox Run Management's Collegium Pharmaceutical position peaked at $253K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.